Advanced Gastrointestinal Cancer Clinical Trial
Official title:
Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients
NCT number | NCT01912131 |
Other study ID # | 13-120 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2013 |
Est. completion date | January 2020 |
Verified date | January 2020 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being done to get individuals' feedback on advanced care planning and decision
making.
This study is divided into two parts (Part 1 and Part 2). The purpose of Part 1 is to survey
people to find out what is important to people with advanced cancer (again, their values,
such as their goals, concerns and sources of support). This has never been done before in the
way the investigators are doing it, and that is why this is called a "pilot" study, which is
where a new method or treatment is being created and evaluated.
The purpose of Part 2 is to see if combining a medical options video with a short interview
about values helps people with how they feel about their medical situation, and what they
know about their medical options for their medical situation.
Status | Completed |
Enrollment | 178 |
Est. completion date | January 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Able to speak, read and understand English well enough to complete study assessments and interviews in the judgement of the consenting professional - 18 years of age and older - Be seen regularly (at least monthly) at an MSKCC GI medical oncology clinic - Has an exocrine GI cancer with MSKCC pathology confirmation at the primary or metastatic anatomic site - Non-metastatic GI cancers are eligible only if the Eastern Cooperative Oncology Group (ECOG) performance status54 is 2,3, or 4 at the time of consent (although patients with locally advanced [stage III] and inoperable pancreatic cancers are eligible regardless of their performance status) - Has a metastatic neuroendocrine histology with MSKCC pathology confirmation as moderately or poorly differentiated or intermediate or high grade - A referring physician's estimate of patient life expectancy must be between 1-12 months. We use this life expectancy range in order to ensure some degree of subject homogeneity for the purpose of sample size and methodologic design. Also, these timeframes were chosen in order to test an intervention in patients with serious illness (under 1 year prognosis). - Part 2 Only: Did not complete Part 1 of the study. Exclusion Criteria: - Short Portable Mental Status Questionnaire (SPMSQ) score of less than "intact mental functioning" (3 or more errors). - Significant psychiatric or cognitive disturbance sufficient, in the consenting professional's or investigator's judgment, to preclude providing informed consent or participating in the interventions (i.e., acute psychiatric symptoms which require individual treatment). |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering at Basking Ridge | Basking Ridge | New Jersey |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | assess the acceptability of this piloted P-COCC intervention | primary outcome is assessed in Part 2 of the study, and is acceptability of this newly- developed P-COCC intervention, as measured by subjects in P-COCC arm who will complete three Likert scale questions examining the degree to which they found the narrative recording process. | 2 years | |
Secondary | quantitative analyses | pre-post scoring on our various psychometric questionnaires (quantitative) and of the subject responses during narrative interviewing (qualitative) | 2 years | |
Secondary | qualitative analyses | pre-post scoring on our various psychometric questionnaires (quantitative) and of the subject responses during narrative interviewing (qualitative) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02008539 -
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
|
Phase 1/Phase 2 | |
Completed |
NCT02024607 -
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02760199 -
89Zr-AMG211 PET Imaging Study
|
Phase 1 | |
Completed |
NCT02677129 -
Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy
|
N/A |